fluoxetine has been researched along with Coma in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Coma: A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe a patient who developed serotonin syndrome on four separate occasions as a result of monotherapy with two different selective serotonin receptor inhibitors (fluoxetine and cetalopram)." | 7.71 | Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. ( Chechani, V, 2002) |
| "To describe a patient who developed serotonin syndrome on four separate occasions as a result of monotherapy with two different selective serotonin receptor inhibitors (fluoxetine and cetalopram)." | 3.71 | Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. ( Chechani, V, 2002) |
| " These children will have no adverse effects or only minimal effects and require no emergency treatment or gastric decontamination." | 1.32 | Fluoxetine exposures: are they safe for children? ( Baker, SD; Morgan, DL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russell, JL | 1 |
| Spiller, HA | 1 |
| Chounthirath, T | 1 |
| Casavant, MJ | 1 |
| Baker, SD | 1 |
| Morgan, DL | 1 |
| Romerio, SC | 1 |
| Radanowicz, V | 1 |
| Schlienger, RG | 1 |
| Chechani, V | 1 |
4 other studies available for fluoxetine and Coma
| Article | Year |
|---|---|
Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
Topics: Child; Child, Preschool; Citalopram; Coma; Dose-Response Relationship, Drug; Evidence-Based Medicine | 2017 |
Fluoxetine exposures: are they safe for children?
Topics: Acute Disease; Age Distribution; Child Welfare; Child, Preschool; Coma; Diarrhea; Dose-Response Rela | 2004 |
[SIADH with epileptic seizures and coma in fluoxetine therapy].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Coma; Depressive Disorder; Electr | 2000 |
Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy.
Topics: Adult; Apnea; Coma; Female; Fluoxetine; Humans; Serotonin Receptor Agonists; Serotonin Syndrome | 2002 |